Cite

    Mark Danta. “Telaprevir triple combination therapy, and dual peginterferon α-2a/ribavirin therapy for 24 weeks for those with rapid-early response is not inferior to 48 weeks of therapy for treatment-naïve patients with genotype 1 hepatitis C virus infection.” Evidence-based medicine, vol. 17, no. 5, 2012, pp. 143–144. http://access.bl.uk/ark:/81055/vdc_100142950786.0x000004